^
    Back
    Association details:
    Biomarker:KIF5B-MET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Tabrecta (capmatinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Front Oncol
    Title:

    Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

    Published date:
    08/11/2022
    Excerpt:
    ...we present a case of a 56-year-old woman diagnosed with KIF5B-MET fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.
    DOI:
    https://doi.org/10.3389/fonc.2022.919123
    Test:
    FoundationOne® CDx